Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Granisetron transdermal - Abeille Pharmaceuticals

Drug Profile

Granisetron transdermal - Abeille Pharmaceuticals

Alternative Names: AB-1001; Granisetron transdermal - Abeille; Inno-P08002; SyB D-0701; SyB-0701

Latest Information Update: 27 Apr 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abeille Pharmaceuticals
  • Developer Abeille Pharmaceuticals; INNOPHARMAX; SymBio Pharmaceuticals
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chemotherapy-induced nausea and vomiting
  • Phase II Radiotherapy-induced nausea and vomiting

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 01 Jun 2015 Phase III development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top